Which big bio­phar­ma play­er should gam­ble $34B on a ripe rare-dis­ease M&A tar­get? An ac­tion-hun­gry top an­a­lyst fills in the blanks

4 weeks ago
Deals

Covid-19 roundup: No­vavax be­gins PhII tri­al in US and Aus­tralia; As­traZeneca signs US man­u­fac­tur­ing deal with Catal­ent

4 weeks ago
Coronavirus

Trump her­alds a 'his­toric break­through' in the R&D fight against Covid-19 — now comes the in­stant back­lash as the FDA pro­vides a con­tro­ver­sial as­sist

4 weeks ago
Regulatory
Coronavirus

How big is the 2020 biotech IPO boom? More than $11 bil­lion big among the year's four dozen en­trants

4 weeks ago
IPOs

Covid-19 roundup: J&J plans 60,000-per­son PhI­II for Sep­tem­ber; Pe­ter Marks draws a red line

4 weeks ago
Coronavirus

De­railed gene ther­a­py study re­ports 3rd death as safe­ty and dura­bil­i­ty is­sues cloud a boom­ing field

4 weeks ago
R&D
Cell/Gene Tx

Bris­tol My­ers joins the lab rush in Cam­bridge with plans to con­sol­i­date R&D ops in a biotech cam­pus now un­der con­struc­tion

5 weeks ago
Pharma

Covid-19 roundup: Pfiz­er/BioN­Tech spell out PhI­II pri­or­i­ty; Le­gal ex­perts urge FDA to re­frain from vac­cine EUAs

5 weeks ago
Coronavirus

In an­oth­er shock­er, FDA re­jects Bio­Marin’s he­mo­phil­ia A gene ther­a­py, de­mand­ing more da­ta on dura­bil­i­ty

5 weeks ago
R&D
Regulatory

J&J inks in­dus­try's lat­est bolt-on buy­out with $6.5B deal to ac­quire Mo­men­ta, beef­ing up its au­toim­mune pipeline

5 weeks ago
Deals

FDA hands Gilead a stun­ning re­jec­tion for block­buster RA can­di­date fil­go­tinib, deal­ing CEO O’Day a ma­jor set­back

Last month
R&D
Regulatory

My­lan wins ear­ly FDA OK of a Tec­fidera knock­off, and they're launch­ing with an eye to top­pling Bio­gen's block­buster fran­chise

Last month
R&D
Regulatory

An MD An­der­son study points to an­oth­er use for No­var­tis’ GSK-born can­cer drugs

Last month
R&D

Eli Lil­ly is bet­ting $1B-plus that it can make yet an­oth­er PD-1 drug a hit in the US. How about a deep dis­count this time?

Last month
R&D

Covid-19 roundup: In­side CTAP: 270 tri­als un­der­way, 570+ in the FDA line; WHO chief calls out 'vac­cine na­tion­al­is­m'

Last month
Coronavirus

New­ly ar­rived on Nas­daq, Po­sei­da qui­et­ly sig­nals a clin­i­cal hold trig­gered by a pa­tient death in PhI — shares crater

Last month
R&D
Regulatory

Daniel O’Day’s I/O dance con­tin­ues, as Gilead and Tan­go ex­pand deal up to $6B

Last month
Deals
Cell/Gene Tx

Ned Sharp­less' 'brain­child' nabs a speedy FDA re­view for small cell lung can­cer drug

Last month
R&D
Regulatory

In blow to an­ti-ag­ing field, Uni­ty Biotech­nol­o­gy fails first ma­jor study, cuts lead pro­gram

Last month
R&D

Covid-19 roundup: Just how much is the ‘first wave’ mar­ket for Covid-19 vac­cines worth? One top an­a­lyst sets the prize at $20B

Last month
Coronavirus

How bad­ly does Sanofi chief Paul Hud­son want Prin­cip­ia? Enough to ink a $3.7B buy­out deal, dou­bling down on MS

Last month
Deals

FDA ap­proves the third NMOSD drug in 18 months as Roche/Genen­tech beefs up its port­fo­lio of drugs for neu­ro­log­i­cal dis­or­ders

Last month
R&D
Regulatory

US gov­ern­ment re­port­ed­ly be­gins prepar­ing for Covid-19 chal­lenge tri­als. Are they eth­i­cal?

Last month
R&D
Coronavirus

Covid-19 roundup: As­traZeneca signs 400M vac­cine sup­ply deal with EU; Sinopharm re­ports pos­i­tive Phase I/II da­ta for vac­cine can­di­date

Last month
Coronavirus
First page Previous page 1234567 Next page Last page